Gradientech
Gradientech is a Swedish in vitro diagnostics company dedicated to supporting modern microbiology labs with cutting-edge solutions for time-critical samples, such as positive blood cultures. Their mission is to develop next-generation diagnostics that provide patients with the right treatment at the right time, supporting clinicians with precise MIC values in record time to improve patient outcomes and reduce healthcare costs and antibiotic resistance. Their vision is "Precision medicine, for a sustainable world." They develop innovative, high-quality, easy-to-use products, including the QuickMIC system, which offers ultra-rapid antibiotic susceptibility testing results in 2-4 hours. The company is committed to quality, sustainability, and advancing healthcare through innovative diagnostics.
Industries
Nr. of Employees
medium (51-250)
Gradientech
Patents
Products
Ultra-rapid AST instrument system
A compact diagnostic instrument platform and single-use test cassettes for rapid phenotypic antibiotic susceptibility testing that yields MIC values in approximately 2–4 hours directly from positive blood cultures.
Ultra-rapid AST instrument system
A compact diagnostic instrument platform and single-use test cassettes for rapid phenotypic antibiotic susceptibility testing that yields MIC values in approximately 2–4 hours directly from positive blood cultures.
Services
Coordination and execution of multicenter clinical and pre-clinical studies to generate evidence for regulatory approvals and clinical adoption.
Field implementation, instrument installation and local evaluations with distributor partners at clinical sites.
Coordination and execution of multicenter clinical and pre-clinical studies to generate evidence for regulatory approvals and clinical adoption.
Field implementation, instrument installation and local evaluations with distributor partners at clinical sites.
Expertise Areas
- Antibiotic susceptibility testing (phenotypic AST)
- Clinical trial management for diagnostics (multicenter and regulatory studies)
- Regulatory compliance for in vitro diagnostics (CE-IVD, IVDR, FDA interactions)
- Microfluidics research and platform development
Key Technologies
- Phenotypic AST directly from blood cultures
- Real-time microscopic/live imaging and image analysis
- Microfluidic diagnostic platforms
- Machine learning algorithms for resistance detection
News & Updates
Gradientech signed an agreement for routine use of QuickMIC® in Bosnia and Herzegovina.
Prof. Rossolini, a Professor of Microbiology and Clinical Microbiology at the University of Florence, joins the Scientific Advisory Board.
Gradientech participated in SVIM 2025, presenting updates and results.
Prof. Rossolini joins as a new member of the Scientific Advisory Board.
The QuickMIC system and its gram-negative panel are CE-IVD marked, making it the fastest growth-based testing system for antibiotic susceptibility in sepsis patients.
QuickMIC is a finalist for the Applied Microbiology International Product of the Year Award 2023.
Gradientech signed an agreement for routine use of QuickMIC® in Bosnia and Herzegovina.
Prof. Rossolini, a Professor of Microbiology and Clinical Microbiology at the University of Florence, joins the Scientific Advisory Board.
Gradientech participated in SVIM 2025, presenting updates and results.
Prof. Rossolini joins as a new member of the Scientific Advisory Board.
The QuickMIC system and its gram-negative panel are CE-IVD marked, making it the fastest growth-based testing system for antibiotic susceptibility in sepsis patients.
QuickMIC is a finalist for the Applied Microbiology International Product of the Year Award 2023.